Replay International Dial-in Number: (404) 537-3406
Conference ID: 3687855
The dial-in replay will be available for 14 days following the call. An audio webcast will be available online at www.lexpharma.com/events, with a webcast replay accessible for 14 days after the call.
About Lexicon Pharmaceuticals
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through its Genome5000™ program, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon advanced one of these medicines to market and has a pipeline of promising drug candidates in discovery and clinical and preclinical development in neuropathic pain, heart failure, diabetes
BioMarin Announces Second Quarter 2021 Financial Results and Corporate Updates
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
BioMarin to Host Second Quarter 2021 Financial Results Conference Call and Webcast on Wednesday, July 28 at 4:30pm ET
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
BioMarin Announces First Quarter 2021 Financial Results and Corporate Updates
- Full-year 2021 Financial Guidance Reaffirmed
- Total Revenues Grew 9% in the First Quarter 2021 Compared to First Quarter 2020, Excluding Kuvan
- Regulatory Actions in Europe for Vosoritide and Valoctocogene Roxaparvovec Tracking as Expected; BioMarin Anticipates CHMP Opinion in June for Vosoritide and June Re-submission of MAA for Valoctocogene Roxaparvovec
- FDA Review of Vosoritide Proceeding; PDUFA Target Action Date Extended to November 20, 2021 to Provide Time for Review of Recently Submitted 2-year Phase 3 Results
News provided by
Share this article
Financial Highlights (in millions of U.S. dollars, except per share data, unaudited)
Conference ID: 6376419
An audio webcast will be accessible through the Investor Relations section of the company s website https://ir.fulcrumtx.com/events-and-presentations. Following the live webcast, an archived replay will also be available.
About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum s proprietary product engine identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The company has advanced losmapimod to Phase 2 clinical development for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and Phase 3 for the treatment of COVID-19. Fulcrum has also advanced FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and beta thalassemia into Phase 1 clinical development.